Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Clinicaltrial registered27 Oct 2026

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

27 Oct 2026: Trial registered · ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
27 Oct 2026
Title
ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
Conditions
EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive
Phase
Phase 3
Study Type
Interventional
Status
Not Yet Recruiting
Countries
China
Country
China
Reference
NCT07897188
Location
China
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Jiangsu Aosaikang Pharmaceutical Co., Ltd.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from China

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.